ArticleGeroScience2025
Heavy alcohol use exacerbates skeletal myopathy in peripheral artery disease.
Article in GeroScience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Peripheral artery disease (PAD) is an age-associated vascular condition that contributes to progressive skeletal muscle dysfunction, marked by oxidative stress, mitochondrial abnormalities, and muscle atrophy. Chronic alcohol misuse independently induces similar myopathic changes. Whether alcohol use disorder (AUD) worsens PAD-related skeletal muscle pathology in humans remains unknown. We analyzed gastrocnemius biopsies from PAD patients with heavy alcohol misuse (PAD-AUD), PAD patients without heavy alcohol misuse (PAD-LA), and non-PAD controls with low-to-no alcohol consumption (CON). Markers of oxidative stress, mitochondrial respiration and myofiber morphometrics were compared across groups. Lower extremity function-including walking distance and ankle plantar flexor strength-was also evaluated. Markers of muscle oxidative stress (4-hydroxynonenal (4-HNE), protein carbonyls, and acetaldehyde), mitochondriopathy and myofiber morphometric damage, were significantly elevated in PAD-LA patients relative to CON. Functional outcomes, including walking ability and muscle strength, were correspondingly reduced in PAD. Notably, these pathological and functional impairments were further exacerbated in PAD-AUD. Interestingly, levels of the alcohol-detoxifying enzyme aldehyde dehydrogenase 2 (ALDH2) were unchanged in PAD-AUD muscle but were significantly upregulated in PAD-LA. Although traditionally recognized for metabolizing alcohol-derived aldehydes, ALDH2 also facilitates the clearance of endogenous reactive aldehydes generated by mitochondrial oxidative stress, including 4-HNE and protein carbonyls. In PAD-LA patients, elevated ALDH2 levels coincided with reduced oxidative stress and mitochondriopathy, whereas PAD-AUD patients exhibited no ALDH2 upregulation and intramuscular pathology was enhanced. These findings implicate ALDH2 dysfunction as a contributing factor to muscle degeneration in PAD-AUD and support its potential as a therapeutic target for attenuating oxidative stress in PAD.
Indexed as
Identifiers
41219664What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.